(Total Views: 387)
Posted On: 06/20/2025 5:17:49 PM
Post# of 154604
It looks like it's just another PD-1 checkpoint inhibitor. They show that it adds a four and half months of life benefit, on top of chemotherapy only. Extensive Small Cell Lung Cancer has metastisized to (possibly) the other lung, bone marrow, and fluid around the heart.
Small Cell Lung Cancer has a strong CCR5 expression, and Leronlimab should be a very viable treatment. This looks like and ideal application for a top tier CCR5 antagonist. Almost every mechanism of action would apply.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10199458/
Small Cell Lung Cancer has a strong CCR5 expression, and Leronlimab should be a very viable treatment. This looks like and ideal application for a top tier CCR5 antagonist. Almost every mechanism of action would apply.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10199458/
(6)
(0)
